While its planned merger with AMAG Pharmaceuticals Inc. and a rival offer for AMAG from hedge fund MSMB Capital Management swirled in the background, Allos Therapeutics Inc. enrolled the first patient in its Phase III randomized trial (PDX-017) evaluating Folotyn (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). The post-approval study is open to newly diagnosed patients with PTCL who have achieved an objective response following initial treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or a CHOP-like regimen.